Publications Oncologists and Patients PARIS Test How to Order News Careers

The Search Engine For Identifying Personalized Cancer Treatments

HOW TO ORDER

Getting started with the PARIS® Test
Call: 833 - 736 - 4163
care@senginemedicine.com

Get Started

Resources for Patients + Oncologist

Patient Pre-Screen

Please complete this pre-screen form if you are interested in more details about the PARIS test, SEngine collaboration, research questions, or clinical indications. Please note: If the patient is currently undergoing any cancer treatment and is responding well, SEngine is unable to accept samples. If recurrence, SEngine can perform the drug test after 2-3 week without treatment. Required notification to Clinical Team is 48hrs prior to procedure date. This form is intended for patient inquiries about the PARIS® Test. If you are interested in collaborating with SEngine in a clinical or research capacity, please email connect@senginemedicine.com. PARIS® Test Eligibility Guidelines: • Confirmed cancer diagnosis with solid tumor refractory to treatment, progression, or stable disease • Confirmed locally advanced/rare cancer with limited therapeutic options • Confirmed three-week washout period of any interventional therapy (exceptions made on case-by-case basis) • Fresh, live biopsy tissue or liquid available for acquisition (must confirm with SEngine Team the specimen type, location, and date for biopsy sample kit shipment) • No Friday biopsy or procedure for sample collection. The PARIS® Test Cannot be Performed If: • Patient has brain-only disease (Unless documented prion-free disease) • Fine Needle Aspirate biopsies are not enough material • Insufficient fresh tumor available for testing

Name *

First Name

Last Name

Email Address *

Phone *

Country

(###)

###

####

Location

State/Providence

Disease Type

You Are A *

Patient

Parent of Patient

Spouse of Patient

Member of Patient's Care Team

Other

Name of your Oncologist or Care Team Contact

Oncologist's Email Address

Oncologist Phone Number

Country

(###)

###

####

How Did You Hear about SEngine

A physician

Internet research

Friend

Media story

Other

You will be contacted by a Clinical Care Coordinator within the next two business days.

Oncologist Pre-Screen

This form is intended for Oncologist/Care Team inquiries about the PARIS® Test. Required notification to Clinical Team is 48 hrs prior to procedure date. If you are interested in collaborating with SEngine in a clinical or research capacity, please email connect@senginemedicine.com. PARIS® Test Eligibility Guidelines: • Confirmed cancer diagnosis with solid tumor refractory to treatment, progression, or stable disease • Confirmed locally advanced/rare cancer with limited therapeutic options • Confirmed three-week washout period of any interventional therapy (exceptions made on case-by-case basis) • Fresh, live biopsy tissue or liquid available for acquisition (must confirm with SEngine Team the specimen type, location, and date for biopsy sample kit shipment) • No Friday biopsy or procedure for sample collection. The PARIS® Test Cannot be Performed If: • Patient has brain-only disease (Unless documented prion-free disease) • Fine Needle Aspirate biopsies are not enough material • Insufficient fresh tumor available for testing

Name *

First Name

Last Name

Email Address *

Phone *

Country

(###)

###

####

Location/ Institution

You Are A *

Physician

Other

Have you ordered the PARIS test previously?

Yes

Inquiring for a

Current Patient

Future Patient

Comments

Please confirm you've read the following: *

I understand that the Treating Physician must complete the PARIS® Test Order Form prior to testing. I understand that I must provide SEngine patient medical, pathological, and genomic records prior to testing. I understand that my patient must sign SEngine’s Informed Consent Form, Patient Authorization Form, and Patient Acknowledgement Form prior to testing. I understand that SEngine requires 4 cores of fresh, unprocessed tumor tissue or 250 mL of ascites/pleural effusions. I understand that the sample can be obtained by core biopsy, punch biopsy, endoscopy, or surgical excision and must be shipped to SEngine in Seattle, WA within 48 hours of the procedure.

I've read and understood the above statement.

How Did You Hear about SEngine

Colleague

Medical conference or presentation

Internet research

Media story

You will be contacted by a Clinical Care Coordinator within the next two business days.

Print Brochure for Your Patients

Please direct questions to the Clinical Team at care@senginemedicine.com or 833-736-4136
Required notification to Clinical Team is 48 hrs prior to procedure date.

The test is private and secure and is available in the U.S. (New York state pending)
PARIS® Test is currently not covered by most insurance companies. Fees apply.

SEngine Precision Medicine’s proprietary approach, known as the PARIS® Test, aids in identifying effective and less toxic therapies available for patients with solid cancer tumors. The PARIS® Test starts with a live tissue sample from a patient's unique tumor extracted during a biopsy. SEngine Precision Medicine scientists receive the live tumor biopsy at its CLIA certified lab in Seattle. The PARIS® Test utilizes hundreds of 3D organoids grown by SEngine Precision Medicine scientists from the patient's unique cancer. The 3D organoids are tested against up to 140 cancer fighting drugs and drug combinations.

COMPLETE PRE-SCREEN →

2018.10.28_SE_0211_OVA_p0_MEGM_ULA_20X_IMG1.jpg — Save the Tumor. Spare the Patient

The patient's oncologist receives test results within two to six weeks. The PARIS® Report is a comprehensive analysis and deep understanding of how an individual’s cancer cells respond to therapies. The SPM Score ranks all therapies based on their response and assists the oncologist and the medical team in outlining a personalized treatment strategy.

CLIA Lab Director Shalini Pereira, PhD. — *CLIA Lab Director* *Shalini Pereira, PhD*.

→ First and only lab in the United States to earn Clinical Laboratory Improvement Amendments (CLIA) certification for a high throughput, high complexity test for all solid tumors. Guided by experienced lab director Shalini Pereira, PhD.

→ See live tumor collection guidelines and publishe d resear ch.

What Patients And Oncologists Say About SEngine

Nov 14, 2022

"My grandmother died of Ovarian Cancer over 50 years ago. I was shocked when I was diagnosed with stage 4 Ovarian Cancer that I was offered the same treatment that she was. I knew right then; the medicine of yesterday wasn't for me. I want personalized treatment options to treat my cancer. The Paris Test provided me with a report that outlined which common cancer medications would work to treat mine. They used my tumor and tested the various medications on it, so I didn't have to go through the try and see approach to treatment. I use data to make informed decisions in every other area of my life. Cancer is no different. The Paris Test is the precision medicine we have been waiting for. "

- Ingrid K., Oncology Patient

Nov 14, 2022

May 9, 2019

“SEngine’s technology deciphers the most potentially effective treatment for cancer patients by testing which of hundreds of drugs and unique drug combinations using patient-derived organoids are the most successful at killing the patient’s cancer. By testing on a patient’s tumor outsider their body - versus giving the drug directly to the patient, SEngine’s approach promises to provide crucial information on treatment’s choices to a patient’s oncologist.”

-Dr. Siddhartha Mukherjee, Pulitzer Prize-winning author, Assistant Professor of Medicine Columbia University, SEngine Precision Medicine Scientific Advisory Board Member

May 9, 2019

“If I had cancer, SEngine is the approach I would want to take. We know the majority of SEngine tests show tumors respond to a drug that would likely not be predicted. SEngine’s proprietary method screens for cancer sensitivity to hundreds of drugs and drug combinations- without exposing patients to toxic and potentially ineffective treatments.”

-Dr. Leland Hartwell - Nobel Prize Laureate / Former President Fred Hutchinson Cancer Center / SEngine Board President

May 9, 2019

“I want to thank both of you for all your assistance and guidance while providing me with information and explanation of materials so important to me and my current medical condition. You were always prompt, courteous, thoughtful and willing to go above and beyond during this process.

-Lisa, Connecticut (Patient)

May 9, 2019

HOME
PARIS TEST
HOW TO ORDER
DRUG DEVELOPMENT
PUBLICATIONS
NEWS
TEAM

For all inquiries related to Business Development, Targets and Drug Development or Investors please contact us at: connect@senginemedicine.com

Are you scheduling a patient for a biopsy or surgery for cancer? Call (833) 736 - 4163 or email care@senginemedicine.com to learn if your patient is eligible for a personalized search of medicines.

IMPORTANT

Your patient’s biopsy must be shipped to us within 48 hrs of procedure on ice, not frozen and not fixed in formalin.

Join Newsletter

Name *

First Name

Last Name

Email *

Company/Institute *

How did you hear about us?

Physician

Friend

Media

Online search

Other

Thank you!

22125 17th Ave SE, Suite 117
Bothell, WA 98021

p. (833) 736-4163
f. (855) 904-0072

Sengine Precision Medicine

401 Terry Avenue North,

Seattle, WA, 98109,

United States

(833) 736-4163 connect@senginemedicine.com

Hours

HOW TO ORDER

Getting started with the PARIS® Test Call: 833 - 736 - 4163care@senginemedicine.com

Get Started

Resources for Patients + Oncologist

Getting started with the PARIS® Test
Call: 833 - 736 - 4163
care@senginemedicine.com